Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose
- 31 January 2013
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 79 (1), 8-13
- https://doi.org/10.1016/j.lungcan.2012.09.018
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- The biology and treatment of EML4-ALK non-small cell lung cancerEuropean Journal of Cancer, 2010
- An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumorsOncogene, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- Raf kinases: Function, regulation and role in human cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancersOncogene, 2002